Conversion of MDCK cell line to suspension culture by transfecting with human siat7e gene and its application for influenza virus production.
MDCK cells are currently being considered as an alternative to embryonated eggs for influenza virus propagation and hemagglutinin (HA) production intended for vaccine manufacturing. MDCK cells were found suitable for the virus production but their inability to grow in suspension burdens the process of scale up and hence their production capability. Anchorage-dependent MDCK cells were converted to anchorage-independent cells, capable of growing in suspension as a result of transfection with the human siat7e gene (ST6GalNac V). This gene was previously identified as having an important role in cellular adhesion when the transcriptions of genes from anchorage-dependent and anchorage-independent HeLa cells were compared. Unlike the parental MDCK cells, the siat7e-expressing cells were capable of growing in shake flasks as suspension cultures, achieving maximum concentration of 7 x 10(5) cells/mL while keeping close to 100% viability throughout the growth phase. In production experiments, the siat7e-expressing cells were infected with the Influenza B/Victoria/504/2000 strain. It was determined that the cell-derived viruses retained similar antigenic properties as those obtained from egg-derived viruses and their nucleotide sequences were identical. The specific production of hemagglutinin (expressed in hemagglutination units per 10(6) cells) from the siat7e-expressing cells was approximately 20 times higher than the specific production from the parental MDCK cells. If this suspension process scales up, the production potential of HA from 10 L of siat7e-expressing cells at a concentration of 10(6) cells/mL would be equivalent to the amount of HA obtained from 10,000 embryonated eggs.
Chu
Chia
C
Department of Chemical and Biomolecular Engineering, Johns Hopkins University, 3400 N. Charles Street, Baltimore, MD 21218, USA.
Lugovtsev
Vladimir
V
Golding
Hana
H
Betenbaugh
Michael
M
Shiloach
Joseph
J
D000818:Animals; D000956:Antigens, Viral / Q000378:metabolism; D002448:Cell Adhesion; D002460:Cell Line; D049109:Cell Proliferation; D004285:Dogs; D015971:Gene Expression Regulation, Enzymologic; D019267:Hemagglutinin Glycoproteins, Influenza Virus / Q000096:biosynthesis; D006801:Humans; D009981:Influenza B virus / Q000502:physiology*; D007700:Kinetics; D011489:Protein Denaturation; D012333:RNA, Messenger / Q000235:genetics; D012799:Sialyltransferases / Q000235:genetics* / Q000378:metabolism; D019076:Transgenes; D014779:Virus Replication
D000956:Antigens, Viral; D019267:Hemagglutinin Glycoproteins, Influenza Virus; D012333:RNA, Messenger; D012799:Sialyltransferases; C038525:CMP-N-acetylneuraminate-alpha-N-acetylgalactosaminide alpha-2,6-sialyltransferase
Metab Eng. 2007 May;9(3):241-51
17240181
J Cell Biol. 1997 Jan 13;136(1):1-4
9026502
Vaccine. 2006 Aug 28;24(35-36):6074-87
16781022
Vaccine. 1998 May-Jun;16(9-10):960-8
9682344
J Cell Biol. 1994 Feb;124(4):619-26
8106557
J Virol Methods. 2004 Sep 1;120(1):23-31
15234806
J Clin Microbiol. 2005 Aug;43(8):4139-46
16081961
Appl Microbiol Biotechnol. 2008 May;79(1):11-22
18340442
Biochim Biophys Acta. 2008 Mar;1780(3):421-33
17991443
Dev Biol Stand. 1999;98:39-51; discussion 73-4
10494958
J Clin Microbiol. 2008 Jul;46(7):2189-94
18480230
Science. 1993 Dec 3;262(5139):1572-5
8248807
Expert Opin Biol Ther. 2004 May;4(5):709-17
15155162
Emerg Infect Dis. 2006 Jan;12(1):61-5
16494719
J Biol Chem. 2003 Jun 20;278(25):22787-94
12668675
FEBS Lett. 1977 Jan 15;73(1):59-63
320038
J Infect Dis. 2000 Mar;181(3):831-7
10720501
Vaccine. 2001 May 14;19(25-26):3444-50
11348709
Vaccine. 2006 Apr 12;24(16):3261-72
16472544
Vaccine. 2008 Oct 23;26(45):5736-40
18761387
Mol Biol Cell. 1994 Sep;5(9):967-75
7841524
Appl Microbiol Biotechnol. 2005 May;67(3):299-305
15660212
Virology. 2007 Sep 1;365(2):315-23
17490701
Glycoconj J. 2000 Mar-Apr;17(3 -4):143-51
11201785
Vaccine. 2001 Mar 21;19(17-19):2716-21
11257414
J Cell Biol. 1996 Apr;133(2):391-403
8609171
Nature. 1978 Jun 1;273(5661):345-9
661946
Vaccine. 2004 Jun 2;22(17-18):2202-8
15149778
Virus Res. 2005 May;109(2):149-57
15763145
Vaccine. 2003 Sep 8;21(25-26):3867-74
12922121
J Ultrastruct Res. 1972 Mar;38(5):500-10
4111070
Invest Ophthalmol Vis Sci. 2006 Jan;47(1):113-9
16384952
J Virol. 2003 Aug;77(15):8418-25
12857911
J Virol. 2004 Feb;78(4):1851-7
14747549
Science. 1996 Jan 26;271(5248):499-502
8560263